ledipasvir

Also Known As:

GS-5885; GS5885; ledipasvir acetonate; methyl ((1S)-1-((1R,3S,4S)-3-(5-(9,9-difluoro-7-(2-((6S)-5-(N-(methoxycarbonyl)- l-valyl)-5-azaspiro(2.4)hept-6-yl)-1H-imidazol-4-yl)-9H-fluoren-2-yl)-1H-benzimidazol-2-yl)-2-azabicyclo(2.2.1)heptane-2-carbonyl)-2-methylpropyl)carbamate

Networked: 251 relevant articles (37 outcomes, 38 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	McHutchison, John G: 23 articles (01/2019 - 07/2012)
2.	Pang, Phillip S: 16 articles (10/2016 - 02/2014)
3.	Brainard, Diana M: 12 articles (10/2020 - 07/2012)
4.	Mo, Hongmei: 11 articles (11/2018 - 07/2012)
5.	Subramanian, G Mani: 10 articles (02/2016 - 03/2014)
6.	Hyland, Robert H: 9 articles (10/2020 - 02/2014)
7.	Gane, Edward J: 8 articles (10/2020 - 03/2014)
8.	Zeuzem, Stefan: 8 articles (11/2018 - 05/2014)
9.	Dvory-Sobol, Hadas: 8 articles (01/2017 - 04/2014)
10.	Lawitz, Eric: 7 articles (10/2020 - 02/2014)

Related Diseases

1.	Infections 09/01/2017 - "Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study." 05/10/2017 - "Ledipasvir, a novel NS5A inhibitor is used in the management of hepatitis C virus infections. " 01/01/2016 - "Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection." 01/01/2014 - "Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection." 08/01/2018 - "Twelve-week treatment with ledipasvir and sofosbuvir (LDV/SOF), a combination of DAAs, is highly effective in patients with hepatitis C virus (HCV) genotype 1 infection. "
2.	Fibrosis (Cirrhosis) 01/01/2019 - "Genotype 1 HCV-infected patients with or without compensated cirrhosis had prior treatment failure to any DAA (part 1) or ledipasvir/SOF (part 2). " 07/01/2017 - "We evaluated the effectiveness and safety in clinical practice of ledipasvir (LDV) plus SOF for Japanese patients infected with HCV genotype 1. This large, multicenter, real-world cohort study consisted of 772 patients treatment-naive or -experienced, with or without compensated cirrhosis, who were treated with LDV (90 mg)/SOF (400 mg) for a fixed 12-week duration. " 06/01/2015 - "Ledipasvir + SOF + RBV for 12 or 24 weeks achieved SVR12 rates of >96 % in post-LT patients including those with compensated cirrhosis. " 02/07/2020 - "We retrospectively analyzed 27 patients who underwent liver transplant due to hepatitis C virus-related cirrhosis and who received ledipasvir-sofosbuvirfor 12 weeks between January 1, 2016 and December 31, 2017 following transplant procedures conducted at the Inonu University Turgut Ozal Medical Center Gastroenterology Department between January 1, 2008 and December 31, 2017. " 10/01/2016 - "The all-oral regimen of ledipasvir and sofosbuvir is an effective and safe treatment for a wide range of HCV 4 subtypes in both treatment-naïve and -experienced patients, including those with compensated cirrhosis. "
3.	Chronic Hepatitis C 08/01/2018 - "Combination treatment of ledipasvir and sofosbuvir (LDV/SOF) is first-line treatment for patients with chronic hepatitis C genotype 1 in the United States, Europe, and Japan. " 10/01/2023 - "Patients with chronic hepatitis C in pregnancy were enrolled and treated with ledipasvir and sofosbuvir after the first trimester. " 12/01/2022 - "A combination of the ledipasvir plus sofosbuvir regimen for 12 weeks is effective and well tolerated, and can be used safely in treating children older than 3 years and adolescent patients with chronic hepatitis C." 03/01/2021 - "Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study." 10/28/2018 - "Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir."
4.	Hepatitis C 07/01/2012 - "A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C." 01/01/2023 - "Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study" 01/01/2021 - "Ledipasvir is a novel antiviral agent used in the treatment of hepatitis C. " 08/15/2018 - "Sofosbuvir (SOF) and ledipasvir (LDS) represent anti-hepatitis C binary mixture. " 08/15/2018 - "New, simple and sensitive HPTLC method for simultaneous determination of anti-hepatitis C sofosbuvir and ledipasvir in rabbit plasma."
5.	COVID-19 01/01/2022 - "The ledipasvir showed excellent docking interactions with the 7NEH, 5YEC, and 5IJC, indicating that it is a perfect candidate for the treatment of COVID-19 patients. " 03/01/2022 - "Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial." 01/01/2022 - "In conclusion, the combination therapy of ledipasvir and itraconazole can be a better alternative for treating COVID-19 patients coinfected with black fungus." 01/01/2022 - "Combination Therapy of Ledipasvir and Itraconazole in the Treatment of COVID-19 Patients Coinfected with Black Fungus: An In Silico Statement." 02/15/2022 - "Sofosbuvir with ledipasvir (SOF/LED) as a combined dosage form was tried at the pandemic COVID 19 crisis. "

Related Drugs and Biologics

1.	Sofosbuvir
2.	Ribavirin (Virazole)
3.	daclatasvir
4.	Simeprevir
5.	paritaprevir
6.	ombitasvir
7.	dasabuvir
8.	Creatinine
9.	Nucleotides
10.	Antiviral Agents (Antivirals)

Related Therapies and Procedures

1.	Liver Transplantation
2.	Therapeutics
3.	Renal Dialysis (Hemodialysis)
4.	Transplantation
5.	Aftercare (After-Treatment)